Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
teprasiran
- Development stage
- Phase 3
- Lead developer
- Quark Pharmaceuticals
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Teprasiran is a synthetic, chemically stabilized small interfering RNA (siRNA) oligonucleotide that acts through RNA interference to temporarily inhibit the expression of the tumor suppressor protein p53. By inhibiting p53-mediated cell death, teprasiran aims to protect renal tubular epithelial cells from injury and reduce the risk of acute kidney injury (AKI), particularly in high-risk patients undergoing cardiac surgery or in kidney transplant recipients at risk for delayed graft function. The drug is administered intravenously and has a short plasma residence time but provides temporary inhibition of p53 for approximately 48–72 hours. Teprasiran has been evaluated in phase 2 and phase 3 clinical trials for prevention of AKI after cardiac surgery and for prevention of delayed graft function following kidney transplantation[1][2][3][6][7].
- Other names
- teprasiran sodium
02
Targets
TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on teprasiran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on teprasiran.